Browsed by
Tag: study

New Study Reveals 450% Surge in Consumers Texting Main Street Businesses, Restaurants and Salons During COVID-19 Pandemic

New Study Reveals 450% Surge in Consumers Texting Main Street Businesses, Restaurants and Salons During COVID-19 Pandemic

Numa research sees significant boost in conversational commerce

Numa, a leading answering service powered by artificial intelligence (AI) that ensures businesses never miss a call or text, today released its latest research on consumer engagement with Main Street businesses. Its infographic, “COVID-19 Changes How Customers Shop at Main Street Businesses,” illustrates surging demand for conversational commerce among consumers and how businesses are evolving communications to service customers in stores and off premises.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005156/en/

STUDY REVEALS 450% SURGE IN CONSUMERS TEXTING MAIN STREET BUSINESSES, RESTAURANTS AND SALONS DURING COVID-19 PANDEMIC. Numa research sees significant boost in conversational commerce. (Graphic: Business Wire)

“Our data, based on actual product usage data from small and medium-sized companies, indicates a shift in customer behavior prompted in large part by the global pandemic and shuttering of businesses,” said Numa Founder and CEO Tasso Roumeliotis. “Even before the crisis, customers had shown a preference for texting with businesses in addition to calling, but over the last several months there has been a dramatic increase in virtual engagement and a desire to communicate across multiple channels.”

Businesses today are not only struggling to meet consumer demand but also to adapt to new operational requirements that bring contactless solutions into the equation. With 98% of all text messages opened and 95% responded to within 3 minutes of being delivered, texting is one of the easiest and most immediate ways for businesses to strengthen consumer relationships—even from afar. Add to that the ability to accommodate curbside pickup and 24/7 communication, which mitigates the impact of limited staff and time away from stores, and businesses immediately possess powerful tools to take them beyond surviving to thriving.

After a deep analysis of user behavior, Numa findings include an increase in

Read the rest
New Study Predicts Gloomy Economic Times Ahead For Americans

New Study Predicts Gloomy Economic Times Ahead For Americans

With unemployment sky rocketing as a result of Covid-19, there has been a corresponding rise in evictions and mortgage defaults. A new study from Washington University in St. Louis’ Olin Business School of the loan-to-value ratios in the wake of the 2008 financial crash issues a cautionary warning about the troubles ahead.

The study finds that the higher the outstanding mortgage is relative to the value of the home, the worse the future income growth and job mobility of the individual will be.

The researchers assessed wage data and credit profiles from around 30 million Americans working in over 5,000 companies. The analysis revealed a negative association between the income of the worker and their home loan-to-value (LTV) ratio, with this especially so when the principle owed was higher than the value of the house.

For instance, when homes were in such negative equity, the homeowner would earn $352, or 5%, less per month than workers with less mortgage debt relative to the value of their home. This situation is often compounded by poor credit or liquidity issues, which can render people unable to move to a new job with better income, or even to a new area. It’s a situation the researchers believe could be exacerbated by the current crisis.

“The impact of the current crisis on local economies varies widely across the U.S.,” the researchers say. “Our study highlights the difficulties someone in a worse-affected area may face in trying to pack up and move to a less-affected region. Furthermore, our study also highlights an important cost of homeownership: For instance, buying a home will constrain your labor mobility, and in the long run that may adversely affect your labor income.”

Precarious finances

The researchers gathered data

Read the rest
Study: Closing UK schools leads to more deaths in lockdown

Study: Closing UK schools leads to more deaths in lockdown

  • A new paper has said that closing UK schools during lockdown led to more COVID-19 deaths than if they had stayed open.
  • The paper, by Professor Graeme Ackland, was published in the British Medical Journal on Wednesday and is a re-analysis of a model published by Imperial College London in March.
  • The Imperial model prompted the UK to enforce a lockdown, in line with many other countries facing outbreaks.
  • But, Ackland argues, some of its provisions were counter-productive. He claims that closings schools and universities in particular likely led to “more deaths compared with the equivalent scenario without the closures.”
  • Visit Business Insider’s homepage for more stories.

A new scientific paper claims that the UK’s decision to close schools and universities in March as part of its lockdown strategy resulted in more COVID-19 deaths than if they stayed open.

The peer-reviewed paper, was written by Graeme Ackland, professor of computer simulation at The University of Edinburgh, was published in the British Medical Journal on Wednesday.

It is a re-analysis of a model published by Imperial College London on March 16.

The Imperial model was hugely significant. It prompted the UK government to abandon its strategy of herd immunity, and impose a series of lockdown measures, including the closure of schools. The paper warned the UK was set for 510,000 deaths in the absence of such action.

In the course of 10 simulations, Ackland said the addition of school closures to other lockdown variables increased the number of deaths.

His argument is that mitigation strategies should focus on keeping the virus from older, more vulnerable people, and not on preventing the spread in settings where most people are young.

FILE PHOTO: Parents walk their children to school on the last day before their official closure, as the spread of the coronavirus disease (COVID-19) continues, in West London, Britain, March 20, 2020. REUTERS/Toby Melville

Parents walk their children to school in West London on March 20, 2020.

Reuters


“Adding school and university closures to case isolation,

Read the rest
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.

In the trial, we observed significant inhibitory effects in a dose dependent manner in all concentration ranges tested. Used as a positive control, Dermavant Sciences’ psoriasis drug tapinarof also showed significant antipsoriatic activity in a preclinical trial using the same mouse model. Our drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations. Derm-Biome’s compound inhibits pro-inflammatory cytokine production, it up-regulates anti-inflammatory mediators including interferons and other anti-inflammatory cytokines, and enhances expression of proteins key to maintaining an effective skin barrier. The compound also promotes skin microbiome diversity by inhibiting the growth of pathogenic bacteria, including staph and C. acnes. 

Dr. Youwen Zhou, Professor in the Department of Dermatology and Skin Science, University of British Columbia: “My group ran both the psoriasis and atopic dermatitis trials for Derm-Biome using well established mouse models that I find accurately mimic these human diseases. I have also used these mouse models for other investigational compounds and FDA approved drugs. The Derm-Biome compound blocked the development of psoriasis and atopic dermatitis in a dose dependent manner, both in terms of inflammation scores and in inhibition of the inflammatory mediators of these diseases. It is a compound with promising potential

Read the rest
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis …

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis …

  • Study did not meet primary endpoint of reducing rate of pulmonary exacerbations
  • Lenabasum treatment had a favorable safety profile and was well-tolerated
  • Data to be presented at the upcoming North American Cystic Fibrosis Conference Oct. 7-23

Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF). The study enrolled patients in the U.S., Canada and Europe at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF.

The CF-002 Phase 2b trial did not meet the primary endpoint of a statistically significant reduction in rate of new PEx per subject per 28 weeks. Lenabasum treatment had a favorable safety profile and was well-tolerated.

The topline data will be presented at the upcoming virtual North American Cystic Fibrosis Conference (NACFC), taking place October 7-23, 2020.

Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus, said, “We are very disappointed that the study did not meet the primary endpoint. We look forward to providing more details of study results starting tomorrow at NACFC. We thank the participants, the staff at study sites, the Cystic Fibrosis Foundation, and the European Cystic Fibrosis Society Clinical Trials for their support and partnership throughout this study.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, said, “We are immensely grateful to the Cystic Fibrosis Foundation for their invaluable support of this program from its inception. It has been a privilege to work with the CF community throughout this development program.”

Phase 2b CF-002 Trial Design

CF-002 was a multinational Phase 2b study evaluating the efficacy and

Read the rest